March 14, 2019
Shares of Atossa Genetics were up over 368 percent on Thursday to close at US$7.07 following the approval from the...
October 26, 2017
Atossa Genetics shared the pricing of an underwritten public offering of 11,500,000 shares of common stock.
July 25, 2017
Atossa Genetics completed enrollment for their Phase 1 dose escalation study of Atossa's proprietary Endoxifen.
June 26, 2017
Atossa Genetics shared a batch of positive interim safety data from its Phase 1 dose escalation study on Endoxifen.
May 19, 2017
Atossa Genetics announced it completed enrollment for a Phase 1 study of Endoxifen.
September 14, 2016
NASDAQ today notified Atossa Genetics that the company was once more compliant with NASDAQ's minimum closing bid price listing rule...
May 1, 2016
StemCells, Biostage and ARCA biopharma round off top five gainers.